European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus

Status Completed

Clinical Trial Summary

By this study, the investigators want to test if the value of adjuvant pulse glucocorticoid therapy for pemphigus can be determined by comparing an experimental arm (dexamethasone pulse therapy, prednisolone, and azathioprine) with a control arm (placebo pulse therapy, prednisolone, and azathioprine). The investigators will determine the rate of complete remission with dexamethasone pulse therapy; the time needed for complete remission; and the duration of remission, and compare these data with those of the placebo arm.

Clinical Trial Description

Pemphigus is a severe chronic dermatological disease which appears to be incurable. Oral glucocorticoid now forms the cornerstone of treatment. From previous uncontrolled studies it has been suggested, that the use of high dose intravenous glucocorticoid pulse therapy may lead to complete remission without further therapy. Prospective placebo-controlled studies of adjuvant pulse therapy for pemphigus are lacking. This prospective, multi-centre, randomised, double-blind, placebo-controlled trial assesses the efficacy and steroid-sparing effect of oral high-dose glucocorticoid pulse therapy as adjuvant added to the standard combination therapy of prednisone and azathioprine in the treatment of pemphigus vulgaris, in terms of complete remission rate (primary endpoint), initial control, disease control, and adverse events. In the experimental arm glucocorticoid pulse therapy is given, comprising monthly pulses with 300mg oral dexamethasone on three consecutive days. In addition the patients receive daily prednisone and azathioprine treatment, the latter dose adjusted to the thiopurine-methyltransferase level. In the control arm the glucocorticoid pulse therapy is replaced double blindly by monthly oral placebo capsules on three consecutive days. in addition the patients receive the same daily combination schedule with prednisone and azathioprine as in the experimental arm. This study design requires 30 patients in each arm, with one year follow-up. Only new patients with pemphigus vulgaris and/or pemphigus oris are included. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Pemphigus

Clinical Trial Details

NCT number	NCT00127764
Study type	Interventional
Source	University Medical Center Groningen
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	January 2001
Completion date	April 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05534776` - Validation of 5-Point Investigator Global Assessments for Pemphigus
Terminated	`NCT00278642` - Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders	Phase 1
Not yet recruiting	`NCT05898308` - Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus	Phase 4
Terminated	`NCT01559155` - Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Active, not recruiting	`NCT01974518` - Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus	Phase 3
Recruiting	`NCT05284929` - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting	`NCT05954416` - FARD (RaDiCo Cohort) (RaDiCo-FARD)
Completed	`NCT00283712` - Use of Infliximab for the Treatment of Pemphigus Vulgaris	Phase 2
Not yet recruiting	`NCT06285435` - Coagulation Activation in Patients With Pemphigus
Not yet recruiting	`NCT06454357` - A Clinical Study of B007 in the Treatment of Pemphigus.	Phase 2/Phase 3
Completed	`NCT01299857` - Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab	Phase 3
Completed	`NCT00960713` - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders	N/A
Completed	`NCT00213512` - Effect of Anti CD20 in Pemphigus Desease	Phase 2/Phase 3
Active, not recruiting	`NCT04400994` - IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus	Phase 2
Recruiting	`NCT02237313` - Identification of Vulnerability Factors in the Course of Pemphigus Patients	N/A
Terminated	`NCT03075904` - A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)	Phase 1/Phase 2
Terminated	`NCT03762265` - A Study of PRN1008 in Patients With Pemphigus	Phase 3
Recruiting	`NCT02365675` - Wound Dressings for Pemphigus and Pemphigoid	N/A
Recruiting	`NCT01338103` - Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex	N/A
Active, not recruiting	`NCT00656656` - Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.